Surya Patra

Sir, my first question is on the Ilumetri getting included in the national reimbursement list of China. Generally, it is believed to be a k ind of a big achievement for any molecule within the 6 months of, or a few months of marketing approval, getting listed into the national reimbursement list. So that is considered to be a big development, big achievement and instant access to the 92%, 95% of the population.

Going forward in FY '25 onwards, because this is effective from the January '24. So the next year would be an important year for us from China side.

Okay. Okay. And sir, is it a kind of a royalty-based model here in China or it is... For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com,